New immunotherapy cocktail aims to beat melanoma relapse

NCT ID NCT02656706

Ongoing Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, given after surgery to patients with stage III or resected stage IV melanoma. The goal is to see if this regimen is safer and more effective than standard high-dose interferon, which is highly toxic. The study enrolled 22 participants and will track side effects and survival outcomes over six months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this combination could offer a more effective and less toxic adjuvant treatment for high-risk melanoma, potentially increasing the chance of long-term remission.
What could go wrong: This is a small phase II trial with only 22 participants, so results may not apply broadly. The drugs can cause serious immune-related side effects, and it is unclear if the combination will be better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Rhode Island Hospital and The Miriam Hospital

Providence, Rhode Island, 02903/02906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.